You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Indicators Under Development

The following indicators are important to provide an accurate and complete picture of how the cancer system is performing across the continuum of care. These indicators are either planned or under development, and will be included in future editions of the Cancer System Quality Index.


  • Patients with invasive breast cancer who have a biopsy
  • Low risk prostate cancer patients who received a bone scan
  • Proportion of lung cancer patients confirmed by biopsy/cytology/pathology
  • Laboratory turnaround times (malignant hematology)
  • Inappropriate chest and abdominal computed tomographies (CTs) (malignant hematology) 


  • Wait times from diagnosis to first treatment (breast, colorectal, lung, prostate)
  • Immediate breast reconstruction rate
  • Combination adjuvant chemotherapy received for women under age 70 with AJCC stage IA (T1c) and IB-III ER/PR negative breast cancer
  • Total mastectomy patients (with 4 or more positive nodes) who received radiotherapy
  • Stage 3 colon cancer patients who received guideline-recommended chemotherapy following surgery
  • Proportion of rectal cancer patients receiving post-operative radiotherapy
  • Proportion of resected stage 2 non-small cell lung cancer patients who received post-operative chemotherapy
  • Active surveillance of low-risk prostate cancer patients
  • High-risk prostate cancer patients receiving adjuvant androgen deprivation therapy (ADT) while undergoing radiotherapy
  • Percentage of survivors transitioned following treatment (malignant hematology) 
  • Re-vaccination rates post stem-cell transplant (malignant hematology) 


  • Emergency department visits in the last 30 days of life (breast, colorectal, lung, prostate)
  • Chemotherapy treatment in last 30 days of life (breast, colorectal, lung, prostate)
  • Physician home visits and/or palliative home care in last 90 days of life (breast, colorectal, lung, prostate)